New Survival Data Keeps Roche Ahead In TIGIT Immunotherapy Race
But Can It Really Challenge Keytruda Dominance?
Roche’s Phase II lung cancer results bode well for SKYSCRAPER readout expected in 2022.
You may also be interested in...
Tiragolumab missed several endpoints in a Phase III metastatic SCLC study, and hopes now rest on its success in NSCLC which presents the bigger market opportunity for the lead candidate in this closely watched new drug class.
Roche has a lot riding on it trials to extend use of Tecentriq to challenge Keytruda in frontline NSCLC – but the wait for its Alzheimer’s readout for gantenerumab will be truly nerve-wracking.
Sanofi has deprioritized its presence in type 1 diabetes in recent years but could help turn teplizumab into a game-changer blockbuster product.